Chimerix Inc (CMRX)

Apr 7, 2025, 11:23 AM EDT - 19 days ago

Top 3 Health Care Stocks That May Crash In Q2

ALMS DERM

Mar 31, 2025, 2:34 PM EDT - 25 days ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CRVO CVS GERN LLY NVO SEPN

Mar 21, 2025, 6:00 AM EDT - 5 weeks ago

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

Mar 10, 2025, 10:33 PM EDT - 6 weeks ago

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

JAZZ

Mar 7, 2025, 4:01 PM EST - 7 weeks ago

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2025, 11:20 AM EST - 7 weeks ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

GLYC

Mar 5, 2025, 8:41 AM EST - 7 weeks ago

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

JAZZ

Mar 5, 2025, 7:14 AM EST - 7 weeks ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

JAZZ

Mar 5, 2025, 7:00 AM EST - 7 weeks ago

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

JAZZ

Feb 20, 2025, 5:25 PM EST - 2 months ago

Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Jan 29, 2025, 4:15 PM EST - 3 months ago

Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

Dec 30, 2024, 7:00 AM EST - 4 months ago

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Dec 11, 2024, 2:19 PM EST - 4 months ago

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 9, 2024, 4:01 PM EST - 4 months ago

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Nov 7, 2024, 9:34 PM EST - 6 months ago

Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 7:00 AM EDT - 6 months ago

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Oct 18, 2024, 4:31 PM EDT - 6 months ago

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2024, 11:50 AM EDT - 9 months ago

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 11 months ago

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 1, 2024, 11:28 AM EDT - 1 year ago

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Mar 1, 2024, 3:31 PM EST - 1 year ago

Chimerix: Tackling A Strong Unmet Need With Promising Data

Feb 29, 2024, 1:42 PM EST - 1 year ago

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Feb 22, 2024, 7:00 AM EST - 1 year ago

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Dec 29, 2023, 7:00 AM EST - 1 year ago

Chimerix Appoints Lisa Decker to Board of Directors

Dec 4, 2023, 7:00 AM EST - 1 year ago

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Nov 16, 2023, 7:00 AM EST - 1 year ago

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Sep 8, 2023, 5:11 AM EDT - 1 year ago

Chimerix: Dangerous Road, Thesis Intact

Aug 16, 2023, 10:05 AM EDT - 1 year ago

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Aug 5, 2023, 1:10 PM EDT - 1 year ago

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 7:00 AM EDT - 1 year ago

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Jul 27, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Jun 27, 2023, 4:05 PM EDT - 1 year ago

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Jun 6, 2023, 4:50 PM EDT - 2 years ago

Chimerix: A High-Risk 'Lottery Ticket'

May 25, 2023, 7:00 AM EDT - 2 years ago

Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

May 6, 2023, 5:41 PM EDT - 2 years ago

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

May 4, 2023, 7:00 AM EDT - 2 years ago

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Apr 27, 2023, 7:00 AM EDT - 2 years ago

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Apr 18, 2023, 4:01 PM EDT - 2 years ago

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Mar 6, 2023, 9:00 AM EST - 2 years ago

Chimerix: Gaining Traction, Cash Runway To 2027

Mar 2, 2023, 10:36 AM EST - 2 years ago

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

Mar 2, 2023, 7:00 AM EST - 2 years ago

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Jan 5, 2023, 7:00 AM EST - 2 years ago

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 8, 2022, 5:00 PM EST - 2 years ago

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update